m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00344)
Target Name Homeobox protein NANOG (NANOG)
Synonyms
Homeobox transcription factor Nanog; hNanog
    Click to Show/Hide
Gene Name NANOG
Chromosomal Location 12p13.31
Family Nanog homeobox family
Function
Transcription regulator involved in inner cell mass and embryonic stem (ES) cells proliferation and self-renewal. Imposes pluripotency on ES cells and prevents their differentiation towards extraembryonic endoderm and trophectoderm lineages. Blocks bone morphogenetic protein-induced mesoderm differentiation of ES cells by physically interacting with SMAD1 and interfering with the recruitment of coactivators to the active SMAD transcriptional complexes. Acts as a transcriptional activator or repressor. Binds optimally to the DNA consensus sequence 5'-TAAT[GT][GT]-3' or 5'-[CG][GA][CG]C[GC]ATTAN[GC]-3'. Binds to the POU5F1/OCT4 promoter. Able to autorepress its expression in differentiating (ES) cells: binds to its own promoter following interaction with ZNF281/ZFP281, leading to recruitment of the NuRD complex and subsequent repression of expression. When overexpressed, promotes cells to enter into S phase and proliferation.
    Click to Show/Hide
Gene ID 79923
Uniprot ID
NANOG_HUMAN
HGNC ID
HGNC:20857
Ensembl Gene ID
ENSG00000111704
KEGG ID
hsa:79923
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
NANOG can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line Soma Mus musculus
Treatment: Mettl3-/- soma
Control: Wild type soma
 GSE171199
Regulation
logFC: 2.74E+00
p-value: 4.57E-02
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary In breast cancer, ZNF217 could upregulate Homeobox protein NANOG (NANOG) by reducing N6-methyladenosine levels via methyltransferase-like 13 (METTL3).
Target Regulation Up regulation
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Cell Process Cell migration
Cell invasion
Epithelial-mesenchymal transition initiation
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
In total 4 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary In glioma, hsa_circ_0072083 could regulate Homeobox protein NANOG (NANOG) and ALKBH5 via targeting miR-1252-5p to control temozolomide resistance. circ_0072083 silence reduced NANOG expression via blocking ALKBH5-mediated demethylation.
Target Regulation Up regulation
Responsed Disease Glioma ICD-11: 2A00.0
 Disease Info 
Responsed Drug Temozolomide Approved
 Drug Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model U251/TR cells (2 × 106 per mouse) with stable transfection of sh-circ_0072083 or sh-NC were subcutaneously injected into mice.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [3]
Response Summary Homeobox protein NANOG (NANOG) activity does not merely compensate for reduced O2 levels but significantly increases ALKBH5, JMJD2C, and TET1 activity in hypoxic breast cancer cells, leading to transcriptional and posttranscriptional changes in gene expression that promote the specification and/or maintenance of BCSCs. ALKBH5 overexpression decreased Homeobox protein NANOG (NANOG) mRNA methylation, increased NANOG levels, and increased the percentage of BCSCs,
Target Regulation Up regulation
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response HIF-1 signaling pathway hsa04066
Cell Process Signaling pathways regulating pluripotency of stem cells (hsa04550)
In-vitro Model BT-474 Invasive breast carcinoma Homo sapiens CVCL_0179
HCC1954 Breast ductal carcinoma Homo sapiens CVCL_1259
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MDA-MB-435 Amelanotic melanoma Homo sapiens CVCL_0417
SUM-149 (Human breast cancer cell SUM149)
SUM-159 (A mesenchymal triple-negative breast cancer cell line)
T-47D Invasive breast carcinoma Homo sapiens CVCL_0553
ZR75.1 A3 Invasive breast carcinoma Homo sapiens CVCL_YX82
In-vivo Model A total of 1,000 breast cancer cells were injected into the mammary fat pad of 6-8-wk-old female NSG mice in a 1:1 suspension of Matrigel (BD Biosciences) in PBS solution. At 10 wk after injection, mice were examined for the presence of tumors, which were harvested for analysis.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene [4]
Response Summary ALKBH5 knockdown in MDA-MB-231 breast cancer cells significantly decreased metastasis from breast to lungs in immunodeficient mice. ALKBH5-mediated demethylation of N6-methyladenosine (m6A) in Homeobox protein NANOG (NANOG) mRNA leading to increased expression of NANOG.
Target Regulation Up regulation
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Cell Process Biological regulation
HIF-1 signaling pathway (hsa04066)
In-vitro Model HCC1954 Breast ductal carcinoma Homo sapiens CVCL_1259
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
SUM-149 (Human breast cancer cell SUM149)
SUM-159 (A mesenchymal triple-negative breast cancer cell line)
T-47D Invasive breast carcinoma Homo sapiens CVCL_0553
ZR75.1 A3 Invasive breast carcinoma Homo sapiens CVCL_YX82
In-vivo Model 1,000 MDA-MB-231 subclone cells were injected into the mammary fat pad of randomly chosen 6-to-8 week-old female severe combined immunodeficiency (SCID) mice in a 1:1 suspension of Matrigel (BD Biosciences) in PBS (n = 7 mice per subclone).
Experiment 4 Reporting the m6A Methylation Regulator of This Target Gene [5]
Response Summary Homeobox protein NANOG (NANOG) served as a target in ALKBH5-mediated m6A modification in ovarian cancer.
Target Regulation Up regulation
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Cell Process Cell invasion
In-vitro Model HEY Ovarian serous adenocarcinoma Homo sapiens CVCL_0297
HO-8910 Endocervical adenocarcinoma Homo sapiens CVCL_6868
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
In-vivo Model Female athymic BALB/c nude mice (4-week-old) were provided (SLAC Laboratory Animal Co. Ltd.). The animals were raised in a pathogen-free animal laboratory and randomly divided into the control or experimental group (six mice in each group).
Brain cancer [ICD-11: 2A00]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary In glioma, hsa_circ_0072083 could regulate Homeobox protein NANOG (NANOG) and ALKBH5 via targeting miR-1252-5p to control temozolomide resistance. circ_0072083 silence reduced NANOG expression via blocking ALKBH5-mediated demethylation.
Responsed Disease Glioma [ICD-11: 2A00.0]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Temozolomide Approved
 Drug Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model U251/TR cells (2 × 106 per mouse) with stable transfection of sh-circ_0072083 or sh-NC were subcutaneously injected into mice.
Breast cancer [ICD-11: 2C60]
 Disease Info 
In total 3 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary In breast cancer, ZNF217 could upregulate Homeobox protein NANOG (NANOG) by reducing N6-methyladenosine levels via methyltransferase-like 13 (METTL3).
Responsed Disease Breast cancer [ICD-11: 2C60]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Cell Process Cell migration
Cell invasion
Epithelial-mesenchymal transition initiation
Experiment 2 Reporting the m6A-centered Disease Response [3]
Response Summary Homeobox protein NANOG (NANOG) activity does not merely compensate for reduced O2 levels but significantly increases ALKBH5, JMJD2C, and TET1 activity in hypoxic breast cancer cells, leading to transcriptional and posttranscriptional changes in gene expression that promote the specification and/or maintenance of BCSCs. ALKBH5 overexpression decreased Homeobox protein NANOG (NANOG) mRNA methylation, increased NANOG levels, and increased the percentage of BCSCs,
Responsed Disease Breast cancer [ICD-11: 2C60]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Pathway Response HIF-1 signaling pathway hsa04066
Cell Process Signaling pathways regulating pluripotency of stem cells (hsa04550)
In-vitro Model BT-474 Invasive breast carcinoma Homo sapiens CVCL_0179
HCC1954 Breast ductal carcinoma Homo sapiens CVCL_1259
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MDA-MB-435 Amelanotic melanoma Homo sapiens CVCL_0417
SUM-149 (Human breast cancer cell SUM149)
SUM-159 (A mesenchymal triple-negative breast cancer cell line)
T-47D Invasive breast carcinoma Homo sapiens CVCL_0553
ZR75.1 A3 Invasive breast carcinoma Homo sapiens CVCL_YX82
In-vivo Model A total of 1,000 breast cancer cells were injected into the mammary fat pad of 6-8-wk-old female NSG mice in a 1:1 suspension of Matrigel (BD Biosciences) in PBS solution. At 10 wk after injection, mice were examined for the presence of tumors, which were harvested for analysis.
Experiment 3 Reporting the m6A-centered Disease Response [4]
Response Summary ALKBH5 knockdown in MDA-MB-231 breast cancer cells significantly decreased metastasis from breast to lungs in immunodeficient mice. ALKBH5-mediated demethylation of N6-methyladenosine (m6A) in Homeobox protein NANOG (NANOG) mRNA leading to increased expression of NANOG.
Responsed Disease Breast cancer [ICD-11: 2C60]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Cell Process Biological regulation
HIF-1 signaling pathway (hsa04066)
In-vitro Model HCC1954 Breast ductal carcinoma Homo sapiens CVCL_1259
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
SUM-149 (Human breast cancer cell SUM149)
SUM-159 (A mesenchymal triple-negative breast cancer cell line)
T-47D Invasive breast carcinoma Homo sapiens CVCL_0553
ZR75.1 A3 Invasive breast carcinoma Homo sapiens CVCL_YX82
In-vivo Model 1,000 MDA-MB-231 subclone cells were injected into the mammary fat pad of randomly chosen 6-to-8 week-old female severe combined immunodeficiency (SCID) mice in a 1:1 suspension of Matrigel (BD Biosciences) in PBS (n = 7 mice per subclone).
Ovarian cancer [ICD-11: 2C73]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [5]
Response Summary Homeobox protein NANOG (NANOG) served as a target in ALKBH5-mediated m6A modification in ovarian cancer.
Responsed Disease Ovarian cancer [ICD-11: 2C73]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Cell Process Cell invasion
In-vitro Model HEY Ovarian serous adenocarcinoma Homo sapiens CVCL_0297
HO-8910 Endocervical adenocarcinoma Homo sapiens CVCL_6868
OVCAR-3 Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
In-vivo Model Female athymic BALB/c nude mice (4-week-old) were provided (SLAC Laboratory Animal Co. Ltd.). The animals were raised in a pathogen-free animal laboratory and randomly divided into the control or experimental group (six mice in each group).
Temozolomide [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [2]
Response Summary In glioma, hsa_circ_0072083 could regulate Homeobox protein NANOG (NANOG) and ALKBH5 via targeting miR-1252-5p to control temozolomide resistance. circ_0072083 silence reduced NANOG expression via blocking ALKBH5-mediated demethylation.
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Glioma ICD-11: 2A00.0
 Disease Info 
Cell Process Cellular Processes
Cell growth and death
Cell apoptosis
In-vitro Model HEK293T Normal Homo sapiens CVCL_0063
U251 (Fibroblasts or fibroblast like cells)
U87 (A primary glioblastoma cell line)
In-vivo Model U251/TR cells (2 × 106 per mouse) with stable transfection of sh-circ_0072083 or sh-NC were subcutaneously injected into mice.
References
Ref 1 MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG. Oncogene. 2022 Mar;41(12):1742-1751. doi: 10.1038/s41388-022-02211-2. Epub 2022 Feb 4.
Ref 2 Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res. 2021 May 11;40(1):164. doi: 10.1186/s13046-021-01942-6.
Ref 3 Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m?A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2047-56. doi: 10.1073/pnas.1602883113. Epub 2016 Mar 21.
Ref 4 Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016 Oct 4;7(40):64527-64542. doi: 10.18632/oncotarget.11743.
Ref 5 RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-KappaB pathway. J Cell Mol Med. 2020 Jun;24(11):6137-6148. doi: 10.1111/jcmm.15228. Epub 2020 Apr 24.